Paia Biotech

PAIA Biotech is an innovative leader in bead-based, high-throughput assay kits and services for the biologics industry, leveraging its patented 384-well plate technology. Founded in 2014 (with operational data suggesting 2018), the company offers a unique platform for screening antibody developability, purity, mispairing, aggregation, and glycan features directly from cell culture supernatants. Its product portfolio and screening services address key bottlenecks in antibody and protein therapeutic development, positioning it as a tools and services provider to accelerate R&D pipelines. The company is privately held and appears to be in a revenue-generating stage, serving a global customer base from its base in Cologne, Germany.

Proprietary bead-based detection technology using specialized 384-well microplates for high-throughput analysis of antibodies and proteins from crude samples. Compatible with standard fluorescence plate readers.

Competes in the bioanalytical tools space against large conglomerates (e.g., Thermo Fisher, Agilent) offering broad portfolios and numerous niche startups focusing on specific assay types. PAIA's differentiation lies in its patented 384-well platform enabling true high-throughput from crude samples, a claim not all competitors can match.